|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
74,175,000 |
Market
Cap: |
1.09(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$12.29 - $35.48 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1065 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
20,976 |
20,976 |
20,976 |
20,976 |
Total Buy Value |
$256,518 |
$256,518 |
$256,518 |
$256,518 |
Total People Bought |
5 |
5 |
5 |
5 |
Total Buy Transactions |
7 |
7 |
7 |
7 |
Total Shares Sold |
4,281 |
22,595 |
141,918 |
232,771 |
Total Sell Value |
$105,494 |
$627,547 |
$4,283,773 |
$7,829,365 |
Total People Sold |
2 |
5 |
6 |
15 |
Total Sell Transactions |
3 |
8 |
11 |
46 |
End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Stack David M |
President and CEO |
|
2013-09-30 |
4 |
OE |
$1.61 |
$24,150 |
D/D |
15,000 |
17,573 |
|
- |
|
Longenecker John P Phd |
Director |
|
2013-09-30 |
4 |
AS |
$46.74 |
$116,850 |
D/D |
(2,500) |
0 |
|
- |
|
Longenecker John P Phd |
Director |
|
2013-09-30 |
4 |
OE |
$1.61 |
$4,025 |
D/D |
2,500 |
2,500 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-09-25 |
4 |
AS |
$47.00 |
$470,000 |
D/D |
(10,000) |
0 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-09-25 |
4 |
OE |
$5.49 |
$54,900 |
D/D |
10,000 |
10,000 |
|
- |
|
Kronenfeld Mark A. |
Director |
|
2013-09-11 |
4 |
B |
$37.01 |
$37,010 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
Wicki Andreas |
Director |
|
2013-09-11 |
4 |
S |
$37.25 |
$662,417 |
I/I |
(17,783) |
1,692,194 |
|
- |
|
Wicki Andreas |
Director |
|
2013-09-11 |
4 |
OE |
$2.69 |
$662,390 |
I/I |
79,033 |
1,707,291 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-08-14 |
4 |
AS |
$37.00 |
$543,900 |
D/D |
(14,700) |
0 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-08-14 |
4 |
OE |
$1.61 |
$23,667 |
D/D |
14,700 |
14,700 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-22 |
4 |
AS |
$35.28 |
$703,508 |
I/I |
(19,938) |
1,630,944 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-19 |
4 |
AS |
$34.98 |
$1,959,524 |
I/I |
(56,020) |
1,650,882 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-18 |
4 |
AS |
$34.80 |
$140,662 |
I/I |
(4,042) |
1,706,902 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-17 |
4 |
AS |
$33.20 |
$714,398 |
I/I |
(21,518) |
1,710,944 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-16 |
4 |
AS |
$33.20 |
$11,620 |
I/I |
(350) |
1,732,462 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-15 |
4 |
AS |
$33.28 |
$1,601,833 |
I/I |
(48,132) |
1,732,812 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-07-12 |
4 |
AS |
$32.00 |
$952,128 |
D/D |
(29,754) |
0 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-07-12 |
4 |
OE |
$1.61 |
$47,904 |
D/D |
29,754 |
29,754 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-11 |
4 |
AS |
$31.48 |
$2,518,416 |
I/I |
(80,000) |
1,780,944 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-05 |
4 |
AS |
$30.80 |
$1,355,961 |
I/I |
(44,021) |
1,860,944 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-03 |
4 |
AS |
$30.67 |
$1,533,300 |
I/I |
(50,000) |
1,904,965 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-02 |
4 |
AS |
$29.85 |
$1,808,820 |
I/I |
(60,597) |
1,954,965 |
|
- |
|
Patou Gary |
Chief Medical Officer |
|
2013-07-02 |
4 |
AS |
$30.00 |
$300,000 |
D/D |
(10,000) |
0 |
|
- |
|
Patou Gary |
Chief Medical Officer |
|
2013-07-02 |
4 |
OE |
$1.61 |
$16,100 |
D/D |
10,000 |
10,000 |
|
- |
|
Wicki Andreas |
Director |
|
2013-07-01 |
4 |
AS |
$29.85 |
$114,952 |
I/I |
(3,851) |
2,015,562 |
|
- |
|
236 Records found
|
|
Page 3 of 10 |
|
|